Biological Agent Reference Sheet (BARS)

The content of this document is for Emory University use only.

The information and contents of this Biological Agent Reference Sheet (including all text and graphics), whether available in print or electronic format (including any digital format, e-mail transmissions, or download from the website), shall be known hereinafter as "Reference Sheet Content." The Reference Sheet Content is provided as a courtesy and is not intended as a sole source of guidance in the evaluation of biological agents. The Reference Sheet Content is not intended to substitute for medical advice, medical care, diagnosis, or treatment obtained from a physician or health care provider. Please seek the advice of a physician or other qualified health care provider with any questions you may have regarding a medical condition. Do not rely on the Reference Sheet Content for diagnosis, treatment, or medical advice. This Reference Sheet Content is for informational purposes and does not provide individualized medical care or treatment. No endorsement of any specific tests, products, or procedures is made by Reference Sheet Content or affiliated party, member, agent or employee of the Emory University Environmental Health and Safety Office.

Environmental Health and Safety Office Research Administration

BIOLOGICAL AGENT REFERENCE SHEET

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

SAS GOV2, 24 followers as 2019 COVID-191 Governor Condition From Joseph Condition Governor Condition G	CHARACTERISTICS https://www.canada.ca/en/public-					
Social pound and Morphology Assistance with a finest 70% similarity in genetic sequence to Morphology Assistance with the outbreak of coronavirus disease first detected in Counter the outbreak of coronavirus disease first detected in Counter 2018 (COVID-19). FORWITH Condition Forwith Condition Social passage in 5-6 week old mice in witro propagation in Very cross. Social passage in 5-6 week old mice in witro propagation in Very cross. FORWITH Condition FORW	CHARACTERISTICS SARS-CoV-2 also known as 2019-nCoV is a ß Coronavirus of		Government of			
Some Constitutes Service And Society Services are a large family of viruses, some causing the outbreads of coronavirus disease first detected in December 2019 (COVID-19). Sorrowth Conditions FIRALTH HAZARDS Coronal/ruses are a large family of viruses, some causing iffinest in people and others that created among animals, and the services of the	_	group 2B with at least 70% similarity in genetic sequence to SARS-CoV. SARS CoV-2 is a Coronavirus responsible for causing the outbreak of Coronavirus disease first detected in				
Leading the outbreak of Coronavirus disease first detected in December 2019 December 2						
### CONTAINMENT ### CO			WHO quidelines			
### ACARD S REALTH HAZARD S			vviio galaeillies			
### ROTATIONS / TREATMENT Vaccines / Prophyluss Properties Value Valu		Serial passage in 5–6-week-old mice. In vitro propagation in	Emory auidelines			
Coronariuses are a large family of virsues, some causing filess in people and others that recutate among ammals, including cameb, cits, and buts. Analysis of the genetic tree of the SARS-Cav2 indicated to riginared in bats, but whether the virus jumped directly from bats or there was an intermediary animal host is not vet known. Inhalation and contact with contaminated surfaces. Person-to purson happens among close contracts with contaminated surfaces. Person-to purson happens among close contracts of product of the person is people being severely ill and dying. Symptoms to people being severely ill and dying. Symptoms to people being severely ill and dying. Symptoms can include, but are not limited to lever, cough, brantes of breath. The human infectious dose of SARS-Cav2 is unknown. Based infectious Dose in the himbaliton route is 36 179 viral particles. Incubation Period. Viaccines / Prophylixids Windows Pressor 214 days MEDICAL PRECAUTIONS / TREATMENT Viaccines / Prophylixids A contract time being and contact with inhalation route is 36 179 viral particles. Windows person 214 days MEDICAL PRECAUTIONS / TREATMENT Viaccines / Prophylixids A contract in many include the antiviral remdesivir, oxygen therapy, airway management, steroids, and the management of co-infection. Report lall epopoures. Complete the health questionnaire and follow occupational health requirements if exposure were to occur. Surveillonce COVID-19 is a reportable disease in the USA in the management of Co-infection. Report lall epopoures. Complete the health questionnaire and follow occupational health requirements if exposure were to occur. Surveillonce COVID-19 is a reportable disease in the USA in the management of Co-infection. Report all epopoures. Complete the health questionnaire and follow occupational health requirements if exposure were to occur. Surveillonce COVID-19 is a reportable disease in the USA in the production of the management of Co-infection. Report all epopoures. Complete the health questionnai	Growth Conditions		, g	SARS-CoV-2		
Coronaviruses are a large family of viruses, some causing fillness in people and others that circulate among aminals, including camels, cats, and bats. Analysis of the genetic tree of the SARS-CoV2 dindicated to ingrinated in bats, but whether the virus jumped directly from bats or there was an intermediary animal host is not yet known. Inhalation and contact with contaminated surfaces. Persontoperson person and person coughts or anezes. Inhalation and contact with contaminated surfaces. Persontoperson happens among close contracts clobust of election person large and surfaces. Persontoperson happens among close contracts clobust of election person large and strongly to occur mainly via respiratory droplets produced when an infection general person coughts or anezes. Signs and Signs and Illinesses have ranged from people with mild symptoms to people being severely III and dying. Symptoms as the people with mild symptoms to people being severely III and dying. Symptoms can include, but are not inflined to fever, cought, shortness of breath. The human infectious dose via the inhalation route is 36-179 viral particles. Incubation Period Incubation Peri	HEALTH HAZARD	os .	CONTAINMENT			
Host Range An initiation and contact with contaminated surfaces. Person- to person happens among close contacts (about 6 feet), spread is thought occur mainly with respiratory deplets produced when an infected person cought or sneezes. Signs and Symptoms Signs and Symptoms Signs and Symptoms Illiesses have ranged from people with mild symptoms to people being severely til and dying. Symptoms can include, but are not limited to fever, cough, shortness of breath. The human infectious dose of SASI-COV-2 is unknown. Based on non-human primate research, the best estimate of the human infectious dose of SASI-COV-2 is unknown. But are not limited to fever, cough, shortness of breath human infectious dose of SASI-COV-2 is unknown. But are not limited to fever, cough, shortness of breath human infectious dose of SASI-COV-2 is unknown. But are not limited to fever, cough, shortness of breath human infectious dose of SASI-COV-2 is unknown. But are not limited to fever, cough, shortness of breath human infectious dose of SASI-COV-2 is unknown. But are not limited to fever, cough, shortness of breath human infectious dose of SASI-COV-2 is unknown. But are not limited to fever, cough, shortness of breath human infectious dose of SASI-COV-2 is unknown. But are not limited to fever, cough, shortness of breath human infectious dose of SASI-COV-2 is unknown. But are not limited to fever, cough, shortness of breath human infectious dose of SASI-COV-2 is unknown. But are not limited to fever, cough, shortness of breath human infectious dose of SASI-COV-2 is unknown. But are not limited to fever, cough, shortness of breath human infectious dose of SASI-COV-2 is unknown. But are not limited to fever, cough shortness, of the sall with paper to the human infectious dose of SASI-COV-2 is unknown. But are not limited to fever, cough shortness of breath human infectious dose of SASI-COV-2 is unknown. But are not limited to fever, cough shortness of breath human infectious of the sall with paper to the human infectious		Coronaviruses are a large family of viruses, some causing illness in people and others that circulate among animals, including camels, cats, and bats. Analysis of the genetic tree of the SARS-CoV-2 indicated it originated in bats, but whether the virus jumped directly from bats or there was an	BSL2		•	
of the SAS CoV2 indicated of originated in bals, but whether the virus jumped directly from bas to there was an intermediary animal host is not yet known. Modes of Exposure inhabition and contact with contaminated surfaces. Person-to-person happens among close contacts (about 6 feet), spread is thought to occur mainly via respiratory droplets produced when an infected person coughts or sneezes. Signs and Symptoms Illinesses have ranged from people with mild symptoms to people being severely ill and drying. Symptoms can include, but are not intend to feever, cough, shortness of feesal to the human infectious dose via the inhabition route is 36-179 wiral particles. Incubation Period. Z-1 d days MEDICAL PRECAUTIONS / TREATMENT Vaccines / Prophylaxis Medical Prophylaxis Reporting of a monochonal antibody cooktail specific for the SASS CoV-2 is who may not respond exposure to the short source of the sharp or the sharp of the sharp or the						
## SIZE/ABSIZ with enhanced practices of the was an intermediary animal host is not yet known. ## SIZE/ABSIZ with enhanced practices. ## BSIZE/ABSIZ with enhanced practices work is BIZE/ABSIZ with enhanced practices. ## BSIZE/ABSIZ with enhanced contains work is a BSIZE/ABSIZ with enhanced practices. ## BSIZE/ABSIZ with enhanced with level 3 practices. By BIZE/ABSIZ with enhanced practices. ## BSIZE/ABSIZ with enhanced practices. ## BSIZE/ABSIZ with enhanced contains with level 3 practices. By BIZE/ABSIZ with enhanced practices. ## BSIZE/ABSIZ with enhanced contains with level 3 practices. By BIZE/ABSIZ with enhanced contains with level 3 practices. By BIZE/ABSIZ with enhanced contains with level 3 practices. By BIZE/ABSIZ with enhanced contains with level 3 practices. By BIZE/ABSIZ with enhanced contains with level 3 practices. By BIZE/ABSIZ with enhanced contains with level 3 practices. By BIZE/ABSIZ with enhanced contains with level 3 practices. By BIZE/ABSIZ with enhanced contains with level 3 practices. By BIZE/ABSIZ with enhanced contains and the BIZE/ABSIZ with enhanced contains and the BIZE/ABSIZ with enhanced contains and the BIZE/ABSIZ with enhanced	Host Range			,		
Inhabition and contact with contaminated surfaces. Personot be proson heppers among dose contacts (about 6 feet), spread is thought to occur mainly via respiratory droplets produced when an infected person coughs or sneeses. Signs and Symptoms	1103t Hunge		BSL2+/ABSL2+	• •		
inhalation and contact with contaminated surfaces. Person- to-person happens among close contacts (about 6 feet), spread is thought to occur aminytiv a reginatory dipets produced when an infected person coughs or sneezes. Signs and Symptoms Illinesses have ranged from people with mild symptoms to people being severely ill and dying. Symptoms can include, but are not limited to fever, cough, shortness of breath. The human infectious does of sacts 5Cvv2 is unknown. Based on non-human primate research, the best estimate of the human infectious does of sacts 5Cvv2 is unknown. Based on non-human primate research, the best estimate of the human infectious does of sacts 5Cvv2 is unknown. Based on non-human primate research, the best estimate of the human infectious does via the inhalation route is 36-179 viral particles. Incubation Period 2-14 days MEDICAL PRECAUTIONS / TREATMENT Currently recommended COVID-19 vaccines in the US are manufactured by Pitzer-BioNTech, Moderna and Novavax. Prophylaxis consisting of a monoclonal antibody cocktail specific for the SARS-Cov2-2 vaccines, and for individuals for whom such vaccines are contraindicated. Peal-Time Reverse Transcriptase (RT)-PCR for use with upper and lower respiratory specimens. Diagnosis & Treatment major include the antiviral remdesivir, oxygen therapy, airway management, steroids, and the management of septic shock, depending on disease severity; in addition to the management of co-infection. Surveillance Enoury Report major the lab. Allow aerosob to settle. Donators with surfaces. SPILL PROCEDURES Notify others working in the lab. Allow aerosob to settle. Donators with surfaces of the spill with paper to whesh and paying and profite for the spill with paper to end not help approved disinfection, working from the period of freed, the paper of the spill with paper to contact time before disposal and claum of position to the search of t				work. BSEZ/ABSEZ With cilitaticea practices.		
Modes of Exposure The hoursh happens among closes contacts (about 6 feet), spread is thought to occur mainly via respiratory droplets produced when an infection generor coughs or sneezes. Signs and Symptoms Illinosess have ranged from people with mild symptoms to people being severely ill and dying. Symptoms can include, but we not limited to fever, cough, shortness of breath. The human infectious dose of SARS-COV-2 is unknown. Based on non-human primate research, the best estimate of the human infectious dose with the halation route is 36-179 viral particles. Incubation Period Vaccines / Prophylaxis consisting of a monoclonal antibody codtail specific for the SARS-CoV-2 pushes in the US are manufactured by Pfizer-BioNTech, Moderna and Novavax. Prophylaxis consisting of a monoclonal antibody codtail specific for the SARS-CoV-2 pushes in the US are manufactured by Pfizer-BioNTech, Moderna and Novavax. Prophylaxis consisting of a monoclonal antibody codtail specific for the SARS-CoV-2 pushes in the US are manufactured by Pfizer-BioNTech, Moderna and Novavax. Prophylaxis consisting of a monoclonal antibody codtail specific for the SARS-CoV-2 pushes in the US are manufactured by Pfizer-BioNTech, Moderna and Novavax. Prophylaxis consisting of a monoclonal antibody codtail specific for the SARS-CoV-2 vaccines, and for individuals for whom such vaccines are contraindicated. Prophylaxis consisting of a monoclonal with upper and lower respiratory specimens. Prophylaxis consisting of a monoclonal with upper and lower respiratory specimens. Prophylaxis consisting of a monoclonal with upper and lower respiratory specimens. Prophylaxis devices are contrained and proper specimens of the specimens of the proper specimens of the p				·		
Signs and Symptoms an infected person coughs or sneezes. Signs and Symptoms an infected person coughs or sneezes. Illnesses have ranged from people with mild symptoms to people being severely ill and dying. Symptoms can include, but are not limited to fever, cough, shortness of breath. The human infectious dose of SARS-COV-2 is unknown. Based on non-human primate research, the best estimate of the human infectious dose via the inhalation route is 36-179 viral particles. Incubation Period Currently renommended COVID-19 vaccines in the US are manufactured by Pilizer-BioNTech, Moderna and Novavax. Prophylaxis Prophylaxis NEDICAL PRECAUTIONS / TREATMENT Currently renommended COVID-19 vaccines in the US are manufactured by Pilizer-BioNTech, Moderna and Novavax. Prophylaxis Prophylaxis Needle State: Diagnass & Treatment may include the antiviral remdesivir, oxygen therapy, airway management, steroids, and the management of co-infection. Surveillance Emory Requirements of SaRS-CoV-2 and the antiviral remdesivir, oxygen therapy, airway management, steroids, and the management of co-infection. Surveillance Emory Requirements of SaRS-CoV-2 However, four Lish have been reported for SARS-CoV-2. However, four Lish shave been reported for SARS-CoV-2. However, four Lish face the point of the spill, noticed shoes, early continued and source and the spill noticed the spill, military and exacute others; in the area, then contact time before disposal and cleanup of spill materials. Contact time before disposal and cleanup of spill materials. Contact time before disposal and cleanup of spill materials. Contact time before disposal and cleanup of the Broad profile of the 4357-3621 of ontext time before disposal and cleanup of the Broad profile of the 4357-3621 of the 446-457-36280. Exposures NEDICAL PRECAUTIONS / TREATMENT Currently recommended COVID-19 vaccines in the US are manufactured by Preceditions of the 458-500 o		to-person happens among close contacts (about 6 feet), spread is thought to occur mainly via respiratory droplets produced when an infected person coughs or sneezes. Illnesses have ranged from people with mild symptoms to people being severely ill and dying. Symptoms can include,				
Signs and symptoms Signs and Symptoms Illnesses have ranged from people with mild symptoms to people being severely III and dying. Symptoms can include, but are not limited to lever, coughly, shortness of hereath. The human infectious dose of SABS-COV-2 is unknown, Based on non-human primate research, the best estimate of the human infectious dose of SABS-COV-2 is unknown. Based on non-human primate research, the best estimate of the human infectious dose wis the inhalation route is 36-179 viral particles. Incubation Period Voccines / Prophylaxis MEDICAL PRECAUTIONS / TREATMENT Currently recommended COVID-19 vaccines in the US are manufactured by Ptige-Biolitic-h, Moderna and Novavax. Prophylaxis consisting of a monoclonal antibody cocitatil specific for the SABS-COV-2 spike protein has been authorized in some jurisdictions for moderately to severely immunocompromised individuals who may not respond adequately to SABS-CoV-2 spike protein has been authorized in some jurisdictions for moderately to severely immunocompromised individuals who may not respond adequately to SABS-CoV-2 spike protein has been authorized in some jurisdictions for moderately to severely immunocompromised individuals who may not respond adequately to SABS-CoV-2 spike protein has been authorized in some jurisdictions for moderately to severely immunocompromised individuals who may not respond adequately to SABS-CoV-2 spike protein has been authorized in some jurisdictions for moderately to severely immunocompromised individuals who may not respond adequately to SABS-CoV-2 spike protein has been authorized in the USA who who will be provided to the provided provided in the USA who will be provided to the provided provided provided in the USA who will be provided to the provided provided provided provided in the USA who will be provided to the provided provided in the USA who will be provided to the provided provided provided in the USA who will be provided by the side of the provided provided provided provided provided provided prov	Modes of Exposure		SPILL PROCEDUR			
Signs and Symptoms on begin being severely ill and dying. Symptoms can include, but are not limited to fever, cough, shortness of breath.	Signs and		Small	Don appropriate PPE. Cover the area of the spill with paper		
Signs and Symptoms Illinesses have ranged from people with mild symptoms to people being severely ill and drying. Symptoms can include, but are not limited to fever, cough, shortness of breath.						
Symptoms people being severely ill and dying. Symptoms can include, but are not limited to fever, cough, shortness of breath. The human infectious dose of SARS-CoV-2 is unknown. Based on non-human primate research, the best estimate of the human infectious dose of SARS-CoV-2 is unknown. Based on non-human primate research, the best estimate of the human infectious dose via the inhalation route is 36-179 viral particles. Incubation Period 2-14 days MEDICAL PRECAUTIONS / TREATMENT Currently recommended COVID-19 vaccines in the US are manufactured by Pitzer-BioNTech, Moderna and Novavax. Prophylaxis Prophylaxis consisting of a monoclonal antibody cocttail specific for the SARS-CoV-2 spike protein has been authorized in some jurisdictions for moderately to severely immunocompromised individuals who may not respond adequately to SARS-CoV-2 spike protein has been authorized in some jurisdictions for moderately to severely immunocompromised individuals who may not respond adequately to SARS-CoV-2 spike protein has been authorized in some jurisdictions for moderately to severely immunocompromised individuals who may not respond adequately to SARS-CoV-2 spike protein has been authorized in some jurisdictions for moderately to severely immunocompromised individuals who may not respond adequately to SARS-CoV-2 spike protein has been authorized in some jurisdictions for moderately to severely immunocompromised individuals who may not respond adequately to SARS-CoV-2 spike protein has been authorized in some jurisdictions for moderately to severely manunocompromised individuals who may not respond adequately to SARS-CoV-2 spike protein has been authorized in some jurisdictions for moderately to severely manunocompromised individuals who may not respond adequately to SARS-CoV-2 spike protein has been authorized in some jurisdictions for moderately to severely manunocompromised individuals who may not respond a deguately to SARS-CoV-2 spike protein has been authorized in some jurisdictions for moderately to sake speci				''' ''' '''		
Use are not limited to fever, cough, shortness of breath. The human infectious dose of SARS-Cov-2 is unknown. Based on non-human primate research, the best estimate of the human infectious dose via the inhalation route is 36-179 viral particles. Incubation Period Incubation Period Vaccines / Prophylavis MEDICAL PRECAUTIONS / TREATMENT Currently recommended COVID-19 vaccines in the US are manufactured by Pfizer-BioNTech, Moderna and Novavax. Prophylavis Prophylavis Prophylavis Prophylavis Prophylavis Reporting Real-Time Reverse Transcriptase (RT)-PCR for use with upper and lower respiratory specimens. Diagnosis & Treatment Real-Time Reverse Transcriptase (RT)-PCR for use with upper and lower respiratory specimens. Treatment may include the antiviral remdesivir, oxygen therapy, airway management, steroids, and the management of septic shock, depending on disease severity, in addition to the management or content fection. Surveillance COVID-19 is a reportable disease in the USA Report all exposures. Complete the health questionnaire and follow occupational health requirements if exposure were to occur. Also have been reported for SARS-CoV-2. However, four faccined in upper and lower respiratory tract specimens, blood, stool. Surveillance COC Ballian Surveillance Sur						
The human infectious dose of SARS-COV-2 is unknown. Based on non-human primate research, the best estimate of the human infectious dose via the inhalation route is 36-179 viral particles. Incubation Period 2-14 days MEDICAL PRECAUTIONS / TREATMENT Currently recommended COVID-19 vaccines in the US are manufactured by Pitzer-BioNTech, Noderna and Novavax. Prophylaxis Prophylaxis Prophylaxis Real-Time Reverse Transcriptase (RT)-PCR for use with upper and lower respiratory specimens. Treatment and incurrently recommended covid the management of espite shock, depending on disease severity, in addition to the management of content follow occupational health requirements if exposure were to occur. Surveillance COVID-19 is a reportable disease in the USA Report all exposures. Complete the health questionnaire and follow occupational health requirements if exposure were to occur. LAB ORATORY HAZARDS COR BMBI CDC guidelines The human infectious dose via the inhalation route is 36-179 viral particles. Large Large contact Emory's Biosafety Officer (104-357-1821) or the ENSPOSURE PROCEDURES Mucous membrane Flush eyes, mouth, or nose for 15 minutes at an eyewash state. After Hours: After Hours: After Exposures Wash area with soap and water for 15 minutes at an eyewash state. After Hours: After Hours: After Hours: After Hours: All GHG-B68-2532 Plush (404-686-587) ENH (404-686-587	Symptoms					
Incubation Period Incubation Period		on non-human primate research, the best estimate of the human infectious dose via the inhalation route is 36-179 viral	Large	I - I		
Incubation Period 2-14 days	Infectious Dose			the EHSO Spill Response Team (404-727-2888).		
Mucuous membrane			EXPOSURE PROCEDURES			
MEDICAL PRECAUTIONS / TREATMENT			Mucous membrane	nus membranel		
Currently recommended COVID-19 vaccines in the US are manufactured by Pfizer-BioNTech, Moderna and Novavax.	Incubation Period	2-14 days				
Currently recommended COVID-19 vaccines in the US are manufactured by Pitzer-BioNTech, Moderna and Novavax. Prophylaxis	MEDICAL PRECAL	UTIONS / TREATMENT	Other Exposures	Wash area with soap and wa		
### Applications of the control of t	WEDICALI RECA	Currently recommended COVID-19 vaccines in the US are				
Prophylaxis consisting of a monoclonal antibody cocktail specific for the SARS-COV-2 spike protein has been authorized in some jurisdictions for moderately to severely immunocompromised individuals who may not respond adequately to SARS-COV-2 vaccines, and for individuals for whom such vaccines are contraindicated. Real-Time Reverse Transcriptase (RT)-PCR for use with upper and lower respiratory specimens. Preatment and incident to the management of septic shock, depending on disease severity, in addition to the management of co-infection. Preatment follow occupational health requirements if exposure were to occur. Preatment speciments Preatment speciment speciments Preatment speciment speciments Preatment speciment sp	-			404-686-8587		
Vaccines / Prophylaxis Prophylaxis ospecific for the SARS-COV-2 spike protein has been reported in some jurisdictions for moderately to severely immunocompromised individuals who may not respond adequately to SARS-CoV-2 vaccines, and for individuals for whom such vaccines are contraindicated. Reporting Immediately report incidents to supervisor. Accidents/Exposures must be reported in H.O.M.E. via HR Self-Service portal. Emory HR website > Self-Service > Workplace Health > Report Diagnosis & Treatment Real-Time Reverse Transcriptase (RT)-PCR for use with upper and lower respiratory specimens. Real-Time Reverse Transcriptase (RT)-PCR for use with upper and lower respiratory specimens. Routine cleaning and disinfection procedures using EPA-registered disinfectants is appropriate, including 10% bleach. Follow manufacturer's recommendations for use – dilution (i.e., concentration), contact time, and care in handling. Surveillance COVID-19 is a reportable disease in the USA Suspected to be inactivated by heat (60°C for 30 minutes) and UV adiation (60 minutes) and UV adiation (6				Needle Stick:	FNDDC	
Prophylaxis Specific for the SARS-CoV-2 spike protein has been authorized in some jurisdictions for moderately to severely immunocompromised individuals who may not respond adequately to SARS-CoV-2 vaccines, and for individuals for whom such vaccines are contraindicated. Page		specific for the SARS-CoV-2 spike protein has been authorized in some jurisdictions for moderately to severely immunocompromised individuals who may not respond adequately to SARS-CoV-2 vaccines, and for individuals for		EUH (404-686-8587)		
in some jurisations for moderately to Severely immunocompromised individuals who may not respond adequately to SARS-CoV-2 vaccines, and for individuals for whom such vaccines are contraindicated. Real-Time Reverse Transcriptase (RT)-PCR for use with upper and lower respiratory specimens.						
Real-Time Reverse Transcriptase (RT)-PCR for use with upper and lower respiratory specimens.				Accidents/Exposures must be reported in H.O.M.E. via HR Self-Service portal. Emory HR website > Self-Service >		
whom such vaccines are contraindicated. Real-Time Reverse Transcriptase (RT)-PCR for use with upper and lower respiratory specimens. Treatment and lower respiratory specimens. Treatment may include the antiviral remdesivir, oxygen therapy, airway management, steroids, and the management of septic shock, depending on disease severity, in addition to the management of co-infection. Surveillance COVID-19 is a reportable disease in the USA Report all exposures. Complete the health questionnaire and follow occupational health requirements if exposure were to occur. LABORATORY HAZARDS Laboratory Acquired Infections (LAIs) Sources SARS-COV-2 RNA has been detected in upper and lower respiratory tract specimens, blood, stool. SUPPLEMENTAL REFERENCES CDC BMBL Biosafety in Microbiological and Biomedical Laboratories, 6 th Edition CDC guidelines Morkplace Health > Report Workplace Health > Report 4 disinfectants is appropriate, including 10% bleach. Follow manufacturer's recommendations for use – dilution (i.e., concentration), contact time, and care in handling. Suspected to be inactivated by heat (60°C for 30 minutes) and UV radiation (60 minutes) It is not known how long the SARS-COV-2 survives on surfaces, preliminary information suggests the virus may survive a few hours or more on dry inanimate surfaces. Bourvival Outside Host Survival Outside Host No LAIs have been reported for SARS-COV-2. However, four LAIs have been reported for SARS-COV-2. However, four LAIs have been reported for SARS-COV-2. However, four LAIs have been reported for SARS-CO			Reporting			
Real-Time Reverse Transcriptase (RT)-PCR for use with upper and lower respiratory specimens. Treatment						
and lower respiratory specimens. Treatment may include the antiviral remdesivir, oxygen therapy, airway management, steroids, and the management of septic shock, depending on disease severity, in addition to the management of co-infection. Surveillance COVID-19 is a reportable disease in the USA Report all exposures. Complete the health questionnaire and follow occupational health requirements if exposure were to occur. LABORATORY HAZARDS Laboratory Acquired Infections (LAIs) Sources SARS-COV-2 RNA has been reported for SARS-COV. SARS-COV-2 RNA has been detected in upper and lower respiratory tract specimens, blood, stool. SUPPLEMENTAL REFERENCES CDC BMBL Biosafety in Microbiological and Biomedical Laboratories, 6th Edition https://www.cdc.gov/covid/index.html https://www.cdc.gov/vaccines/covid-19/info-by-	-	and lower respiratory specimens. Treatment may include the antiviral remdesivir, oxygen therapy, airway management, steroids, and the management of septic shock, depending on disease severity, in addition to				
Treatment by include the antiviral remdesivir, oxygen therapy, airway management, steroids, and the management of septic shock, depending on disease severity, in addition to the management of co-infection. Surveillance COVID-19 is a reportable disease in the USA Report all exposures. Complete the health questionnaire and follow occupational health requirements if exposure were to occur. LABORATORY HAZARDS Laboratory Acquired Infections (LAIs) Sources Sources Biosafety in Microbiological and Biomedical Laboratories, 6th Edition LOC BMBL CDC guidelines Treatment may include the antiviral remdesivir, oxygen therapy, airway management, steroids, and the management of septic shock, depending on disease severity, in addition to the management of septic shock, depending on disease severity, in addition to the management of septic shock, depending on disease severity, in addition to the management of septic shock, depending on disease severity, in addition to the management of septic shock, depending on disease severity, in addition to the management of septic shock, depending on disease severity, in addition to the management of septic shock, depending on disease severity, in addition to the management of septic shock, depending on disease severity, in addition to the management of co-infection. Surpetion (i.e., concentration), contact time, and care in handling. Suspected to be inactivated by heat (60°C for 30 minutes) and UV radiation (60 minutes) It is not known how long the SARS-CoV-2 survives on surfaces, preliminary information suggests the virus may survive a few hours or more on dry inanimate surfaces. PERSONAL PROTECTIVE EQUIPMENT (PPE) • Lab coat, gloves, closed-toed shoes, eye protection with side shield, and face shield if there is a risk of splashes or aerosolization. Enhanced practices require the use of disposable fluid resistant gown in addition to the lab coat, double gloves and N95 respirator [Annual fit testing is required per Emory's Respiratory Protection Program]. All procedures			Disinfection	registered disinfectants is appropriate, including 10% bleach. Follow manufacturer's recommendations for use – dilution		
Treatment any include the antiviral remdesivir, oxygen therapy, airway management, steroids, and the management of septic shock, depending on disease severity, in addition to the management of co-infection. Surveillance COVID-19 is a reportable disease in the USA Report all exposures. Complete the health questionnaire and follow occupational health requirements if exposure were to occur. LABORATORY HAZARDS Laboratory Acquired Infections (LAIs) Surveillance CDC BMBL Biosafety in Microbiological and Biomedical Laboratories, 6th Edition https://www.cdc.gov/covid/index.html https://www.cdc.gov/covid/index.html https://www.cdc.gov/vaccines/covid-19/info-by-						
surveillance COVID-19 is a reportable disease in the USA Emory Requirements Report all exposures. Complete the health questionnaire and follow occupational health requirements if exposure were to occur. LABORATORY HAZARDS Laboratory Acquired Infections (LAIs) Sarces SARS-CoV-2 RNA has been detected in upper and lower respiratory tract specimens, blood, stool. SUPPLEMENTAL REFERENCES CDC BMBL Biosafety in Microbiological and Biomedical Laboratories, 6th Edition https://www.cdc.gov/covid/index.html bichights in addition to the Inflantagenient of septics shock, depending on disease severity, in addition to the management of co-infections. Surveillance COVID-19 is a reportable disease in the USA Survival Outside Host Survival Outside Host Minimum PPE Requirements Minimum PPE Requirements Minimum PPE Requirements Additional Precautions Additional Precautions Additional Precautions Additional Precautions Additional Biosafety in Microbiological and Biomedical Laboratories, 6th Edition https://www.cdc.gov/vaccines/covid-19/info-by-			Distrijection			
the management of co-infection. Surveillance COVID-19 is a reportable disease in the USA Report all exposures. Complete the health questionnaire and follow occupational health requirements if exposure were to occur. LABORATORY HAZARDS Laboratory Acquired Infections (LAIs) Sources SARS-COV-2 RNA has been detected in upper and lower respiratory tract specimens, blood, stool. SUPPLEMENTAL REFERENCES CDC BMBL Biosafety in Microbiological and Biomedical Laboratories, 6th Edition LTDS quidelines the management of co-infection. Minimum PS Survival Outside Host With survive a few hours or more on dry inanimate surfaces. PERSONAL PROTECTIVE EQUIPMENT (PPE) Lab coat, gloves, closed-toed shoes, eye protection with side shield, and face shield if there is a risk of splashes or aerosolization. Enhanced practices require the use of disposable fluid resistant gown in addition to the lab coat, double gloves and N95 respiratory Protection Program]. Additional Precautions Additional Precautions Additional Precautions Additional Precautions Minimum PPE Requirements Additional Precautions Additional Precautions						
Surveillance COVID-19 is a reportable disease in the USA Report all exposures. Complete the health questionnaire and follow occupational health requirements if exposure were to occur. LABORATORY HAZARDS Laboratory Acquired Infections (LAIs) Sources SARS-COV-2 RNA has been detected in upper and lower respiratory tract specimens, blood, stool. SUPPLEMENTAL REFERENCES CDC BMBL Biosafety in Microbiological and Biomedical Laboratories, 6th Edition https://www.cdc.gov/covid/index.html https://www.cdc.gov/covid/index.html https://www.cdc.gov/vaccines/covid-19/info-by- It is not known how long the SARS-COV-2 survives on surfaces, preliminary information suggests the virus may survive a few hours or more on dry inanimate surfaces. PERSONAL PROTECTIVE EQUIPMENT (PPE) • Lab coat, gloves, closed-toed shoes, eye protection with side shield, and face shield if there is a risk of splashes or aerosolization. Enhanced practices require the use of disposable fluid resistant gown in addition to the lab coat, double gloves and N95 respirator [Annual fit testing is required per Emory's Respiratory Protection Program]. Additional Precautions			Inactivation			
Report all exposures. Complete the health questionnaire and follow occupational health requirements if exposure were to occur. Requirements Requirements Report all exposures. Complete the health questionnaire and follow occupational health requirements if exposure were to occur. LABORATORY HAZARDS Laboratory Acquired Infections (LAIs) SARS-CoV-2 RNA has been reported for SARS-CoV. SARS-CoV-2 RNA has been detected in upper and lower respiratory tract specimens, blood, stool. SUPPLEMENTAL REFERENCES Biosafety in Microbiological and Biomedical Laboratories, 6th Edition https://www.cdc.gov/covid/index.html https://www.cdc.gov/vaccines/covid-19/info-by- CDC guidelines COVID-19 is a reportable disease in the USA Host surfaces, preliminary information suggests the virus may survive a few hours or more on dry inanimate surfaces. PERSONAL PROTECTIVE EQUIPMENT (PPE) Lab coat, gloves, closed-toed shoes, eye protection with side shield, and face shield if there is a risk of splashes or aerosolization. Enhanced practices require the use of disposable fluid resistant gown in addition to the lab coat, double gloves and N95 respiratory Protection Program]. All procedures involving live virus or samples potentially infected should be conducted in a biological safety cabinet (BSC). Hand hygiene should be performed as the last step in doffing PPE and before exiting the facility. The use of needles, syringes, and other sharp objects must be approved by the Biosafety office. Waste must be autoclaved before disposal			6	, , ,		
Report all exposures. Complete the health questionnaire and follow occupational health requirements if exposure were to occur. LABORATORY HAZARDS Laboratory Acquired Infections (LAIs) SARS-COV-2 RNA has been reported for SARS-COV. Sources SARS-COV-2 RNA has been detected in upper and lower respiratory tract specimens, blood, stool.				surfaces, preliminary informa	ation suggests the virus may	
CDC guidelines Tollow occupational health requirements if exposure were to occur. PERSONAL PROTECTIVE EQUIPMENT (PPE)				survive a few hours or more	on dry inanimate surfaces.	
LABORATORY HAZARDS Laboratory Acquired Infections (LAIs) Sources SARS-CoV-2 RNA has been detected in upper and lower respiratory tract specimens, blood, stool. SUPPLEMENTAL REFERENCES CDC BMBL Biosafety in Microbiological and Biomedical Laboratories, 6th Edition https://www.cdc.gov/covid/index.html https://www.cdc.gov/vaccines/covid-19/info-by- Minimum PPE Requirements Minimum PPE Requirements Minimum PPE Requirements Minimum PPE Requirements Additional precautions Additional Precautions No Lals have been reported for SARS-CoV-2. However, four disposable fluid resistant gown in addition to the lab coat, double gloves and N95 respirator [Annual fit testing is required per Emory's Respiratory Protection Program]. Additional Precautions	•	follow occupational health requirements if exposure were to	PERSONAL PROT	PROTECTIVE EQUIPMENT (PPE)		
Laboratory Acquired Infections (LAIs) Sources SARS-COV-2 RNA has been detected in upper and lower respiratory tract specimens, blood, stool. SUPPLEMENTAL REFERENCES CDC BMBL Biosafety in Microbiological and Biomedical Laboratories, 6th Edition https://www.cdc.gov/covid/index.html https://www.cdc.gov/vaccines/covid-19/info-by- Minimum PPE Requirements Minimum PPE Requirements Minimum PPE Requirements Additional Precautions Minimum PPE Requirements Additional Precautions Additional Precautions Biosafety in Microbiological and Biomedical Laboratories, 6th configuration as the last step in doffing PPE and before exiting the facility. The use of needles, syringes, and other sharp objects must be approved by the Biosafety office. Waste must be autoclaved before disposal	neganements	occur.				
Lals have been reported for SARS-CoV-2. However, four LAIs have been reported for SARS-CoV-2. However, four LAIs have been reported for SARS-CoV-3. However, four double gloves and N95 respirator [Annual fit testing is required per Emory's Respiratory Protection Program]. SUPPLEMENTAL REFERENCES Additional Edition Additional Precautions Additional Precautions Additional Precautions Additional Precautions Precauti	LABORATORY HA	AZARDS	Minimum BBE	I -	·	
Sources SARS-COV-2 RNA has been detected in upper and lower respiratory tract specimens, blood, stool. SUPPLEMENTAL REFERENCES CDC BMBL Biosafety in Microbiological and Biomedical Laboratories, 6 th Edition https://www.cdc.gov/covid/index.html https://www.cdc.gov/vaccines/covid-19/info-by- Additional Precautions Additional Precautions Additional Precautions Additional Precautions Biosafety office. Waste must be autoclaved before disposal		•				
SARS-COV-2 RNA has been detected in upper and lower respiratory tract specimens, blood, stool. SUPPLEMENTAL REFERENCES CDC BMBL Biosafety in Microbiological and Biomedical Laboratories, 6 th Edition CDC guidelines CDC guidelines SARS-COV-2 RNA has been detected in upper and lower required per Emory's Respiratory Protection Program]. All procedures involving live virus or samples potentially infected should be conducted in a biological safety cabinet (BSC). Hand hygiene should be performed as the last step in doffing PPE and before exiting the facility. The use of needles, syringes, and other sharp objects must be approved by the Biosafety office. Waste must be autoclaved before disposal		·	gan ements	-		
SUPPLEMENTAL REFERENCES CDC BMBL Biosafety in Microbiological and Biomedical Laboratories, 6th Edition https://www.cdc.gov/covid/index.html https://www.cdc.gov/vaccines/covid-19/info-by- Additional Precautions Additional Precautions Additional Precautions Additional Precautions	Sources	• •				
CDC BMBL Biosafety in Microbiological and Biomedical Laboratories, 6 th Edition https://www.cdc.gov/covid/index.html https://www.cdc.gov/vaccines/covid-19/info-by- Additional Precautions Additional Precautions Additional Precautions Syringes, and other sharp objects must be approved by the Biosafety office. Waste must be autoclaved before disposal	SUDDIEMENTAL					
CDC BMBL Edition Additional Precautions Additional Precautions Additional Precautions Syringes, and other sharp objects must be approved by the Biosafety office. Waste must be autoclaved before disposal	SUPPLEIVIENTAL			9 ,		
https://www.cdc.gov/covid/index.html CDC guidelines https://www.cdc.gov/vaccines/covid-19/info-by- Syringes, and other sharp objects must be approved by the Biosafety office. Waste must be autoclaved before disposal	CDC BMBL					
			Precautions	syringes, and other sharp objects must be approved by the		
<u>product/index.html</u> through Emory's approved vendor.	CDC guidelines			T		
		product/index.html		through Emory's approved v	endor.	

BARS_SARS-CoV-2_3 Revision Date: 28-Feb-25 page **2** of **2**